Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials
Repository Usage Stats
<jats:p>The availability of high-fidelity animal models for oncology research has grown enormously in recent years, enabling preclinical studies relevant to prevention, diagnosis, and treatment of cancer to be undertaken. This has led to increased opportunities to conduct co-clinical trials, which are studies on patients that are carried out parallel to or sequentially with animal models of cancer that mirror the biology of the patients’ tumors. Patient-derived xenografts (PDX) and genetically engineered mouse models (GEMM) are considered to be the models that best represent human disease and have high translational value. Notably, one element of co-clinical trials that still needs significant optimization is quantitative imaging. The National Cancer Institute has organized a Co-Clinical Imaging Resource Program (CIRP) network to establish best practices for co-clinical imaging and to optimize translational quantitative imaging methodologies. This overview describes the ten co-clinical trials of investigators from eleven institutions who are currently supported by the CIRP initiative and are members of the Animal Models and Co-clinical Trials (AMCT) Working Group. Each team describes their corresponding clinical trial, type of cancer targeted, rationale for choice of animal models, therapy, and imaging modalities. The strengths and weaknesses of the co-clinical trial design and the challenges encountered are considered. The rich research resources generated by the members of the AMCT Working Group will benefit the broad research community and improve the quality and translational impact of imaging in co-clinical trials.</jats:p>
Published Version (Please cite this version)
Peehl, Donna M, Cristian T Badea, Thomas L Chenevert, Heike E Daldrup-Link, Li Ding, Lacey E Dobrolecki, A McGarry Houghton, Paul E Kinahan, et al. (n.d.). Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. Tomography, 9(2). pp. 657–680. 10.3390/tomography9020053 Retrieved from https://hdl.handle.net/10161/26762.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
- Our lab's research focus lies primarily in developing novel quantitative imaging systems, reconstruction algorithms and analysis methods. My major expertise is in preclinical CT.
- Currently, we are particularly interested in developing novel strategies for spectral CT imaging using nanoparticle-based contrast agents for theranostics (i.e. therapy and diagnostics).
- We are also engaged in developing new approaches for multidimensional CT image reconstruction suitable to address difficult undersampling cases in cardiac and spectral CT (dual energy and photon counting) using compressed sensing and/or deep learning.
- We are involved in co-clinical cancer trials and I serve as the Principal Investigator on the U24 Duke Preclinical Research Resources for Quantitative Imaging Biomarkers part of the NCI Co-Clinical Imaging Research Resources Program network (CIRP).
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.